A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(34 sites)
United States
Xentria Investigative Site, Birmingham, Alabama Xentria Investigative Site, Denver, Colorado Xentria Investigative Site, Jacksonville, Florida Xentria Investigative Site, Chicago, Illinois Xentria Investigative Site, Chicago, Illinois Xentria Investigative Site, Iowa City, Iowa Xentria Investigative Site, Baltimore, Maryland Xentria Investigative Site, Detroit, Michigan Xentria Investigative Site, Minneapolis, Minnesota Xentria Investigative Site, Albany, New York Xentria Investigative Site, New York, New York Xentria Investigative Site, Greenville, North Carolina Xentria Investigative Site, Cincinnati, Ohio Xentria Investigative Site, Philadelphia, Pennsylvania Xentria Investigative Site, Charleston, South Carolina Xentria Investigative Site, Houston, Texas Xentria Investigative Site, Charlottesville, Virginia Czechia
Xentria Investigative Site, Prague Denmark
Xentria Investigative Site, Aalborg Xentria Investigative Site, Aarhus Xentria Investigative Site, Odense Xentria Investigative Site, Roskilde Xentria Investigative Site, Vejle Poland
Xentria Investigative Site, Bielsk Podlaski Xentria Investigative Site, Lodz Spain
Xentria Investigative Site, Barcelona Xentria Investigative Site, Barcelona Xentria Investigative Site, Seville United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, England University College London Hospitals NHS Foundation Trust, London, England King's College Hospital NHS Foundation Trust, London, England Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, England Oxford University Hospitals NHS Foundation Trust, Oxford, England NHS Tayside, Perth, Scotland Last updated November 2025